Credit Rating Reaffirmation
Ipca Laboratories Receives Affirmation of India Ratings for Bank Facilities and Commercial Paper Stock
NSE
IPCALAB
BSE
524494
Ipca Laboratories Limited has informed the stock exchanges that India Ratings & Research (Fitch Group) has affirmed the company’s credit ratings for its bank loan facilities and commercial paper programme. The ratings continue to reflect the company’s strong credit profile and stable outlook.
PRICE-SENSITIVE TRIGGER
Event: India Ratings & Research affirmed the company’s credit ratings for bank facilities and commercial paper.
Type: Credit Rating Reaffirmation
Impact: Positive
Immediate Effect: Reaffirms Ipca’s strong credit profile and continued access to debt financing at existing ratings.
highlight:
- Commercial Paper: IND A1+ (Affirmed) | ₹500 million
- Bank Loan Facilities: IND AA+ / Stable / IND A1+ (Affirmed) | ₹22,481.10 million (reduced from ₹25,937.30 million)
What Happened ?
Ipca Laboratories Limited announced that India Ratings & Research (A Fitch Group Company) has reviewed and affirmed the company’s existing credit ratings for its commercial paper programme and bank loan facilities.
The reaffirmation covers a ₹500 million Commercial Paper programme, rated IND A1+, and Bank Loan Facilities of ₹22,481.10 million, rated IND AA+ / Stable / IND A1+. The company also disclosed that the size of the bank loan facilities has been reduced from ₹25,937.30 million.
Key Details
Operational Highlights:
- India Ratings & Research has affirmed all assigned ratings.
- Commercial Paper programme of ₹500 million continues to carry an IND A1+ rating.
- Bank Loan Facilities of ₹22,481.10 million have been affirmed at IND AA+ / Stable / IND A1+.
- The sanctioned bank loan facilities have been reduced from ₹25,937.30 million.
- Commercial Paper has a maturity of up to 365 days.
- The Commercial Paper programme is not carved out of the company’s fund-based working capital limits.
Note:
- The filing relates solely to a credit rating review and does not represent new borrowing, fundraising, or any change in the company’s capital structure.
Risk Analysis
Summary:
- The reaffirmed ratings indicate continued confidence in Ipca Laboratories’ credit quality. Future rating actions will depend on the company’s financial performance, leverage, and liquidity profile.
Key Risks:
- Future ratings remain subject to periodic review by the rating agency.
- Any deterioration in financial metrics or liquidity could impact ratings.
- Higher leverage or adverse operating performance may influence future credit assessments.
Worst Case:
- A future rating downgrade could increase borrowing costs and reduce financing flexibility.
Risk Level: Low
Company Commentary
- India Ratings & Research has affirmed the company’s ratings for both commercial paper and bank loan facilities.
- The Commercial Paper programme continues to be rated IND A1+.
- Bank Loan Facilities retain the IND AA+ / Stable / IND A1+ rating.
- The company disclosed the updated size of its bank loan facilities following the review.
Official Exchange Filing: Ipca Laboratories Limited
